Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02781454 · ClinicalTrials.gov registry record · Phase 2
Mexiletine in Sporadic Amyotrophic Lateral Sclerosis
A Phase 2 study, sponsored by University of Washington.
- Completed
- Registry status
- Phase 2
- Development phase
- 20
- Enrollment target
NCT02781454 is a Phase 2 study that has completed, run by University of Washington. The registered enrollment target is 20 participants.
The verdict
NCT02781454, a Phase 2 study, has completed, sponsored by University of Washington.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 20 participants
- Enrollment target
Study Summary
The purpose of this research study is to find out whether the drug mexiletine will be effective in lowering motor neuron electrical activity in the brains and nerves in the arms of people with ALS. The investigators will also determine if there are any signs that the drug may slow down the progression of ALS and reduce muscle cramps and muscle twitching. This will be determined through transcranial magnetic stimulation (TMS) and threshold tracking nerve conduction studies (TTNCS). In this trial, the participants will be taking either 300mg/day of mexiletine, 600mg/day of mexiletine, or placebo (non-active study drug).
Interventions
- DRUG Placebo
- DRUG Mexiletine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2016-10 |
| Est. Completion | 2018-09-30 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02781454
The ClinicalTrials.gov registry entry for NCT02781454 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 20 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Washington, which has 1,048 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT02781454 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02781454 about?
NCT02781454 is a clinical study titled "Mexiletine in Sporadic Amyotrophic Lateral Sclerosis". The purpose of this research study is to find out whether the drug mexiletine will be effective in lowering motor neuron electrical activity in the brains and nerves in the arms of people with ALS. The investigators will also determine if there are any signs that the drug may slow down the progressi...
What is the current status of trial NCT02781454?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 20 participants. The study started on 2016-10. Estimated completion is 2018-09-30.
What interventions are being tested in trial NCT02781454?
The interventions under investigation include: Placebo (DRUG), Mexiletine (DRUG).
Who is sponsoring clinical trial NCT02781454?
This trial is sponsored by University of Washington, which has 1,048 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.